Compare IDYA & MTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | MTRN |
|---|---|---|
| Founded | 2015 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2019 | 2000 |
| Metric | IDYA | MTRN |
|---|---|---|
| Price | $27.99 | $205.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $52.86 | $52.50 |
| AVG Volume (30 Days) | ★ 1.4M | 222.0K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.32% |
| EPS Growth | 61.90 | ★ 1178.57 |
| EPS | N/A | ★ 0.92 |
| Revenue | ★ $218,710,000.00 | N/A |
| Revenue This Year | N/A | $15.31 |
| Revenue Next Year | $201.05 | $7.57 |
| P/E Ratio | ★ N/A | $218.55 |
| Revenue Growth | ★ 3024.43 | N/A |
| 52 Week Low | $17.17 | $73.61 |
| 52 Week High | $39.28 | $204.83 |
| Indicator | IDYA | MTRN |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 72.58 |
| Support Level | $26.05 | $113.78 |
| Resistance Level | $28.05 | N/A |
| Average True Range (ATR) | 1.15 | 8.85 |
| MACD | -0.12 | 1.26 |
| Stochastic Oscillator | 7.68 | 99.65 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Materion Corp specializes in the development of specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings. The company operates in four reportable segments: Performance Materials, Electronic Materials, Precision Optics, and Others. The majority of revenue is derived from Electronic Materials which produces chemicals, microelectronics packaging, precious metal, non-precious metal, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms. The Performance Materials segment provides engineered solutions comprised of beryllium and non-beryllium-containing alloy systems and custom-engineered parts.